Clinical Trial

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Name: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — clinical trial record (NCT05882045)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TRIUMPH-3

Completed Phase 3

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Protocol Amendment History 1 change

critical Trial completed 2026-07-31

Trial Details

NCT Number	NCT05882045
Lead Sponsor	Eli Lilly and Company
Conditions	Obesity, Cardiovascular Diseases
Enrollment	1,946 participants
Start Date	2023-05-30
Primary Completion	2026-04-16 (estimated)
Study Completion	2026-05-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-30